Figure 6 | Scientific Reports

Figure 6

From: TCR–like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus–transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants

Figure 6

TCR-like mAbs mediate CDC against EBV BLCLs of HLA-A*02 variants. Six different EBV BLCLs were incubated with the respective antibodies (10 μg/mL) before the addition of baby rabbit complement and assessment of CDC by (A) LDH release and (B) cellular vitality. A*11:01 BLCL CM863 and A*24:02 BLCL WGP47 were included as control cell lines. Values were expressed as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (unpaired student’s t-test).

Back to article page